Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes
Open accessThe DOI matches its Crossref record; 113 of the 113 references it cites were found in a registry or an index; 50 of the 105 sources its claims cite were checked for support.
Abstract
The discovery of long-acting incretin receptor agonists represents a major stride forward in tackling the dual epidemic of obesity and diabetes. Here we outline the evolution of incretin-based pharmacotherapy, from exendin-4 to the discovery of the multi-incretin hormone receptor agonists that look set to be our next step toward curing diabetes and obesity. We discuss the multiagonists currently in clinical trials and the improvement in efficacy each new generation of these drugs bring. The success of these agents in preclinical models and clinical trials suggests a promising future for multiagonists in the treatment of metabolic diseases, with the most recent glucose-dependent insulinotropic peptide receptor:glucagon-like peptide 1 receptor:glucagon receptor (GIPR:GLP-1R:GCGR) triagonists rivaling the efficacy of bariatric surgery. However, further research is needed to fully understand how these therapies exert their effect on body weight and in the last section we cover open questions about the potential mechanisms of multiagonist drugs, and the understanding of how gut-brain communication can be leveraged to achieve sustained body weight loss without adverse effects.
Overview
CoChat Summary
TL;DR
This review traces the evolution from GLP-1 monoagonists to dual and triple incretin co-agonists as increasingly effective therapies for obesity and diabetes. It argues that the newest triagonists, especially retatrutide, approach bariatric-surgery-level weight loss, but key mechanisms and long-term effects remain unresolved.
Key findings
- Exenatide, the first FDA-approved incretin agonist for diabetes, reduced HbA1c by −0.8% at 5 μg and −1.0% at 10 μg after 30 weeks, and both doses reduced body weight.
- Once-weekly semaglutide 2.4 mg produced −14.9% body-weight reduction in adults with obesity, with improved glucose homeostasis and reduced cardiovascular risk.
- In DIO mice, a balanced GLP-1/glucagon dual agonist produced about 10% greater body-weight reduction than a GLP-1R-favoring version, with similar effects on glucose tolerance.
- Retatrutide showed very large effects: in phase 2 obesity data, 60%, 75%, and 83% of participants on 4, 8, and 12 mg lost at least 15% of body weight by 48 weeks, and the 12 mg dose produced a mean 24.2% weight reduction; in diabetes, 72% of participants with prediabetes returned to normoglycemia vs 22% on placebo.
Methods
- Narrative review of previously published preclinical and clinical studies on incretin monoagonists, dual agonists, and triagonists; no new human or animal experiments were conducted by the authors.
- Synthesizes evidence from DIO mouse studies and human clinical trials, including phase 1, phase 2, and phase 3 studies of agents such as cotadutide, survodutide, mazdutide, tirzepatide, HM15211, and retatrutide.
- Main analysis is qualitative comparison of efficacy, safety/tolerability, and proposed mechanisms across drug classes.
Limitations
- The paper explicitly says that the precise mechanisms driving body-weight reduction remain obscure, especially for the enhanced effects of multiagonism.
- It also states that further research is needed to understand which brain regions, cell types, and downstream circuits mediate incretin effects, and to clarify long-term weight maintenance and lean-mass preservation.
- Evident from the text: this is a review, so its conclusions depend on previously published studies rather than original data collection; the paper says this directly by noting it contains no new studies.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Synergies in mechanisms that regulate body weight and glucose metabolism by incretin agonism across tissues in humans [22, 23, 106]. Different incretin agonists exert complementary effects on key peripheral organs and the brain to both directly and indirectly affect energy and glucose. GIP glucose-dependent insulinotropic polypeptide, GLP-1 glucagon-like protein 1. Created by BioRender.com](https://figures.cochat.ai/paper-figures/6a80cf2b750a4269b1761ba9e6750bdf/dual-and-triple-incretin-based-co-agonists-novel-therapeutics-for-obesity-and-figure-1.jpg)
![Fig. 2 A The amino acid sequence of a GLP-1R/GCGR dual agonist MK1462 [116], B the amino acid sequence of the GLP-1R/GIPR dual agonist tirzepatide [117], and C the amino acid sequence of a triagonist [99]. These multiagonists are an assemblage of parts from each incretin and incorporated lessons learned from prior incretin mimetics: Aib substitute to prevent degradation by DPP4, acylation from liraglutide or semaglutide to increase solubility, and the CEX tail from exendin-4. GCGR glucagon receptor, GIPR GIP receptor, GLP-1R GLP-1 receptor, Aib 2-aminoisobutyric acid, DPP4 dipeptidyl peptidase 4, CEX C-terminal extension](https://figures.cochat.ai/paper-figures/e95e537f71114ac6b6e8937aec699804/dual-and-triple-incretin-based-co-agonists-novel-therapeutics-for-obesity-and-figure-2.jpg)
Verification
Claims the paper makes
34 Valid · 0 Not valid · 35 Not checked · 11 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Despite the development, approval and widespread prescription and use of drugs for the treatment of obesity, we have for a long time lacked highly effective anti-obesity drugs [5].”
§ Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes > Introduction
What the sources say
- Supportedcites [5] Müller TD Blüher M Tschöp MH DiMarchi RD Anti-obesity drug discovery: advances and challenges Nat Rev Drug Discov 2022 21 3 201 223 10.1038/s41573-021-00337-8 34815532 PMC8609996 source
The Introduction describes drugs approved for obesity treatment and identifies phentermine as commonly prescribed. The History of AOMs says most approaches could not achieve placebo-adjusted mean weight loss greater than 10% at tolerable doses, while noting a recently approved exception, semaglutide 2.4 mg. This supports the claim's historical framing. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, most of these efforts have been plagued with significant adverse effects and/or limited efficacy which has resulted in the withdrawal and discontinued use for the majority of these medications [5].”
§ Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes > Introduction
What the sources say
- Partly supportedcites [5] Müller TD Blüher M Tschöp MH DiMarchi RD Anti-obesity drug discovery: advances and challenges Nat Rev Drug Discov 2022 21 3 201 223 10.1038/s41573-021-00337-8 34815532 PMC8609996 sourceExperimental — accuracy not yet measured
The History of AOMs section says many earlier drugs were withdrawn over serious adverse effects and that most approaches struggled to achieve substantial weight loss at tolerable doses. It does not say that a majority of medications were withdrawn or discontinued, and it lists several that remain in use. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“strategies for inhibiting ghrelin signaling have thus far not produced viable pharmacotherapies for obesity, but this is an ongoing area of research [15, 16].”
§ Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes > Introduction
What the sources say
- Supportedcites [15] Hagemann CA Jensen MS Holm S LEAP2 reduces postprandial glucose excursions and ad libitum food intake in healthy men Cell Rep Med 2022 3 4 100582 10.1016/j.xcrm.2022.100582 35492241 PMC9043997 source
The Introduction says that GHSR and ghrelin have been considered therapeutic targets, but that no viable clinical candidate has been developed despite two decades of research. It also describes LEAP2 as a potential future target for obesity, consistent with research being ongoing. (LLM, conf=0.93)
- Supportedcites [16] Müller TD Nogueiras R Andermann ML Ghrelin Mol Metab 2015 4 6 437 460 10.1016/j.molmet.2015.03.005 26042199 PMC4443295 source
Section 7.1.2 says ghrelin antagonists were developed as antiobesity drugs but do not appear to have chronic appetite-suppressing effects. Section 7.3 describes continued efforts to block ghrelin action and presents GOAT inhibitors as an opportunity, with weight-loss results in mice rather than an established obesity treatment. Together, these passages support the claim that inhibition had not yet yielded a viable obesity pharmacotherapy and remained under investigation; page numbers were not available in our copy. (LLM, conf=0.86)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Contrary to early loss of function studies that suggested that GIPR drove an increase in body weight, there is no evidence that GIPR agonism increases body weight [85, 86].”
§ Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes > GLP-1/GIP Dual Agonist
What the sources say
- Supportedcites [85] Campbell JE Targeting the GIPR for obesity: to agonize or antagonize? Potential mechanisms Mol Metab 2021 46 101139 10.1016/j.molmet.2020.101139 33290902 PMC8085569 source
Section 3.3 states that no studies reported GIP enhancing weight gain and that the evidence on GIPR agonism does not support the view that it drives weight gain. Section 3.2.2 likewise reports no evidence that chronic GIPR agonism induces weight gain in preclinical models. (LLM, conf=0.94)
- Partly supportedcites [86] Mroz PA Finan B Gelfanov V Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism Mol Metab 2019 20 51 62 10.1016/j.molmet.2018.12.001 30578168 PMC6358549 sourceExperimental — accuracy not yet measured
The Introduction says GIPR mono-agonists do not promote further weight gain in mice with established obesity, and the Results report weight loss with an agonist in diet-induced obese mice. The claim omits that population and treatment context: this paper does not establish that there is no evidence of weight gain from GIPR agonism in any setting. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“An optimized GIP agonist, exhibiting full potency for the human GIPR that also acts as an agonist at the mouse GIPR, induced a reduction in body weight and blood glucose in GLP-1R knockout mice but not GIPR knockout mice [46, 86].”
§ Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes > GLP-1/GIP Dual Agonist
What the sources say
- Supportedcites [46] Zhang Q Delessa CT Augustin R The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling Cell Metab 2021 33 4 833 844.e5 10.1016/j.cmet.2021.01.015 33571454 PMC8035082 source
The Results section on chronic peripheral acyl-GIP treatment reports reduced body weight in GLP-1R knockout mice but no weight-lowering effect in global Gipr knockout mice (Figure 6; page not provided). The Discussion states that acyl-GIP had no effect on body weight or glycemia in global Gipr knockout mice, while its effects were preserved in GLP-1R knockout mice. (LLM, conf=0.90)
- Supportedcites [86] Mroz PA Finan B Gelfanov V Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism Mol Metab 2019 20 51 62 10.1016/j.molmet.2018.12.001 30578168 PMC6358549 source
The Results sections on in vivo GIPR activity and body-weight lowering report that hGIP Aib2 lowered blood glucose and body weight in Glp1r−/− mice, but not in Gipr−/− mice. The glucose result followed an acute dose; the body-weight result followed chronic treatment of diet-induced obese mice. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
36 more claims · 15 with their cited sources checked
Create a free account to see all 80 claims and every source verdict.
- It may state two separate claims as one. 34
- Probably not a substantial claim. 6
- The quote only partly states this claim. 1
Citations
Cites
Positional cloning of the mouse obese gene and its human homologue
Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., & Friedman, J. M. (1994) · Nature · doi:10.1038/372425a0 · Cited by 13,419 · cited 1×
“This new paradigm began with the discovery of leptin, by Jeff Friedman and others in 1994, the first hormone whose primary function is the regulation of body weight, by signaling from the adipose tissue to pro-opiomelanocortin (POMC) neurons [6] in the hypothalamus to reduce food intake.”
MethodMurray, C. J. L., Aravkin, A. Y., Zheng, P., Abbafati, C., Abbas, K. M., Abbasi-Kangevari, M., Abd-Allah, F., Abdelalim, A., Abdollahi, M., Abdollahpour, I., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30752-2 · Cited by 9,854 · cited 1×
“The global prevalence of obesity and diabetes continues to surge, contributing significantly to morbidity and mortality through diseases like heart disease and cancer [1].”
BackgroundGhrelin is a growth-hormone-releasing acylated peptide from stomach
Kojima, M., Hosoda, H., Date, Y., Nakazato, M., Matsuo, H., & Kangawa, K. (1999) · Nature · doi:10.1038/45230 · Cited by 8,479 · cited 1×
“This was followed by the discovery of an opposing hormone, ghrelin, which facilitates signaling from the gut and acts on agouti-related peptide (AgRP) neurons in the hypothalamus to increase food intake [7, 8].”
BackgroundLiraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“Created by BioRender.com liraglutide and semaglutide, but not exenatide, had a lower risk of non-fatal myocardial infarction and stroke [66, 70, 71] and another GLP-1R agonist, dulaglutide, reduced major adverse cardiovascular events [72].”
BackgroundSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 2×
“A once-weekly injection of 2.4 mg of semaglutide resulted in a remarkable reduction in body weight by − 14.9% in adults with obesity, along with substantial improvements in glucose homeostasis and reduced risk of cardiovascular events [66, 67].”
BackgroundInfluentialOnce-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 1×
“A once-weekly injection of 2.4 mg of semaglutide resulted in a remarkable reduction in body weight by − 14.9% in adults with obesity, along with substantial improvements in glucose homeostasis and reduced risk of cardiovascular events [66, 67].”
BackgroundInfluentialGenetic studies of body mass index yield new insights for obesity biology
Study, T. L. C., Locke, A. E., The ADIPOGen Consortium, The AGEN-BMI Working Group, The CARDIOGRAMplusC4D Consortium, The CKDGen Consortium, The, G. L. G. C., The, I. C. B. P., The MAGIC Investigators, The MuTHER Consortium, et al. (2015) · Nature · doi:10.1038/nature14177 · Cited by 4,534 · cited 1×
“…of leptin has revolved around the idea that BMI has a genetic basis, with approximately 40–70% of the variation in BMI in the population being attributable to heritable factors [9], and that the majority of genetic variation associated with BMI is in the central nervous sys-tem (CNS) [10].”
BackgroundGhrelin induces adiposity in rodents
Tschöp, M., Smiley, D. L., & Heiman, M. L. (2000) · Nature · doi:10.1038/35038090 · Cited by 3,949 · cited 1×
“This was followed by the discovery of an opposing hormone, ghrelin, which facilitates signaling from the gut and acts on agouti-related peptide (AgRP) neurons in the hypothalamus to increase food intake [7, 8].”
BackgroundSelf-citationTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 1×
“In its phase 3 trial in adults with obesity, the highest dose of 15 mg once weekly produced an average reduction in body weight of 22.5% after 72 weeks of treatment [91], and a 15.7% reduction in body weight in patients with obesity and diabetes [92].”
BackgroundInfluentialSemaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236 · cited 1×
“…patients with overweight or obesity and established cardiovascular disease, but no diabetes, that were treated with semaglutide had a significantly lower composite of cardiovascular events (death from cardiovascular causes, nonfatal myocardial infarction, and nonfatal stroke) than placebo [73].”
BackgroundGerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163 · cited 1×
“Created by BioRender.com liraglutide and semaglutide, but not exenatide, had a lower risk of non-fatal myocardial infarction and stroke [66, 70, 71] and another GLP-1R agonist, dulaglutide, reduced major adverse cardiovascular events [72].”
BackgroundA Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724 · cited 1×
“This early success of this first GLP-1R agonist drug has been followed by a number of GLP-1 analogues, including liraglutide [64, 65] and semaglutide, which has completely transformed the landscape of obesity.”
BackgroundWeight and Type 2 Diabetes after Bariatric Surgery: Systematic Review and Meta-analysis
Buchwald, H., Estok, R., Fahrbach, K., Banel, D., Jensen, M. D., Pories, W. J., Bantle, J. P., & Sledge, I. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.09.041 · Cited by 2,551 · cited 1×
“…medications, GLP-1R monoagonism still falls short of the efficacy of bariatric surgery in treating obesity and diabetes, which resolves type 2 diabetes (T2D) for more than 80% of patients and produces an average of 25–33% reduction in body weight depending on the type of surgery employed [77, 78].”
BackgroundLixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409 · cited 1×
“Another GLP-1R agonist, lixisenatide, which, like liraglutide and sema-glutide, improves glycemic control and was also well tolerated in patients with type 2 diabetes [68], did not have an increase in cardiovascular events in patients with higher risk [69].”
BackgroundEffects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
Holman, R. R., Bethel, M. A., Mentz, R. J., Thompson, V. P., Lokhnygina, Y., Buse, J. B., Chan, J. C., Choi, J., Gustavson, S. M., Iqbal, N., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612917 · Cited by 2,162 · cited 1×
“Created by BioRender.com liraglutide and semaglutide, but not exenatide, had a lower risk of non-fatal myocardial infarction and stroke [66, 70, 71] and another GLP-1R agonist, dulaglutide, reduced major adverse cardiovascular events [72].”
BackgroundTirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096 · cited 1×
“Critically, the most frequent adverse events with tirzepa-tide, mild to moderate gastrointestinal events, including vomiting (5–10%), diarrhea (12–16%), and nausea (17–22%), were not higher than semaglutide in SUPRASS-2 [97].”
BackgroundEffects of Recombinant Leptin Therapy in a Child with Congenital Leptin Deficiency
Farooqi, I. S., Jebb, S. A., Langmack, G., Lawrence, E., Cheetham, C. H., Prentice, A. M., Hughes, I. A., McCamish, M. A., & O'Rahilly, S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909163411204 · Cited by 1,998 · cited 1×
“Unfortunately leptin mimetics have failed to provide significant weight loss outside the cases of leptin-replacement therapy for patients with genetic leptin deficiency [12, 13].”
BackgroundGlucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928 · cited 1×
“Initially characterized as the second incretin hormone [51], GLP-1 was later found to have pleiotropic action well outside the pancreas, with broad action in the brain and the periphery and which includes decrease of gastric emptying, inhibition of food intake, increase of natriuresis and diuresis,…”
BackgroundGlucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868 · cited 2×
“…and which includes decrease of gastric emptying, inhibition of food intake, increase of natriuresis and diuresis, modulation of rodent β -cell proliferation, decrease of inflammation and apoptosis, improvement of cardio-vascular function, and modulation of learning and reward behavior [52] (Fig.”
BackgroundSelf-citationChang, S.-H., Stoll, C. R. T., Song, J., Varela, J. E., Eagon, C. J., & Colditz, G. A. (2014) · JAMA Surgery · doi:10.1001/jamasurg.2013.3654 · Cited by 1,688
Genetic and Environmental Factors in Relative Body Weight and Human Adiposity
Maes, H. H. M., Neale, M. C., & Eaves, L. J. (1997) · Behavior Genetics · doi:10.1023/a:1025635913927 · Cited by 1,515 · cited 1×
“…of leptin has revolved around the idea that BMI has a genetic basis, with approximately 40–70% of the variation in BMI in the population being attributable to heritable factors [9], and that the majority of genetic variation associated with BMI is in the central nervous sys-tem (CNS) [10].”
BackgroundPharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500 · cited 2×
“GLP-1R is accordingly also found in the heart, and kidney, while GIPR is also expressed in the brain, adipose tissue, stomach, small intestine, bone, and heart [56].”
BackgroundHeymsfield, S. B., Greenberg, A. S., Fujioka, K., Dixon, R. M., Kushner, R., Hunt, T., Lubina, J. A., Patane, J., Self, B., Hunt, P., et al. (1999) · JAMA · doi:10.1001/jama.282.16.1568 · Cited by 1,422 · cited 1×
“Unfortunately leptin mimetics have failed to provide significant weight loss outside the cases of leptin-replacement therapy for patients with genetic leptin deficiency [12, 13].”
BackgroundBenefits and Risks of Bariatric Surgery in Adults: A Review
Arterburn, D. E., Telem, D. A., Kushner, R. F., & Courcoulas, A. P. (2020) · JAMA · doi:10.1001/jama.2020.12567 · Cited by 1,251 · cited 1×
“The procedures involve the removal of approximately 80% of the stomach or attaching the jejunum directly to the upper portion of the stomach, respectively [79].”
BackgroundKendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177 · cited 1×
“Importantly, both arms of the trial showed a significant reduction in body weight [63].”
BackgroundTriple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2301972 · Cited by 1,174
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161 · cited 1×
“GIP and GLP-1 are both degraded very quickly by dipeptidyl peptidase 4 (DPP4) [57–59], making analogues of these endogenous hormones poor drug candidates.”
BackgroundA frameshift mutation in MC4R associated with dominantly inherited human obesity
Yeo, G. S. H., Farooqi, I. S., Aminian, S., Halsall, D. J., Stanhope, R. G., & O'Rahilly, S. (1998) · Nature Genetics · doi:10.1038/2404 · Cited by 1,159 · cited 1×
“A prominent example of a specific mutation associated with obesity was the discovery that a four base-pair deletion in the melanocortin-4 receptor (MC4R) leads to obesity by inhibiting the leptin-melanocortin pathway [11].”
BackgroundWilding, J. P. H., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konakli, K., Lingvay, I., McGowan, B. M., Oral, T. K., Rosenstock, J., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14725 · Cited by 1,128 · cited 1×
“Patients who discontinue semaglutide therapy and have lost weight tend to regain it fairly quickly [110].”
BackgroundKieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Rosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Fernández Landó, L., Mao, H., Cui, X., Karanikas, C. A., & Thieu, V. T. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01324-6 · Cited by 1,080 · cited 1×
“In the SURPASS trials, tirzepatide consistently outper-formed placebo and active comparators in reducing HbA1c across all doses [90, 93–96].”
MethodMüller, T. D., Nogueiras, R., Andermann, M. L., Andrews, Z. B., Anker, S. D., Argente, J., Batterham, R. L., Benoit, S. C., Bowers, C. Y., Broglio, F., et al. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2015.03.005 · Cited by 1,034 · cited 1×
“Likewise, while ghrelin has the potential to be a useful treatment for cancer cachexia [14], strategies for inhibiting ghrelin signaling have thus far not produced viable pharmacotherapies for obesity, but this is an ongoing area of research [15, 16].”
BackgroundSelf-citationAnti-obesity drug discovery: advances and challenges
Müller, T. D., Blüher, M., Tschöp, M. H., & DiMarchi, R. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00337-8 · Cited by 1,021 · cited 3×
“However, most of these efforts have been plagued with significant adverse effects and/or limited efficacy which has resulted in the withdrawal and discontinued use for the majority of these medications [5].”
BackgroundSelf-citationEng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42531-8 · Cited by 1,000 · cited 2×
“Exendin-4 shares a large portion of its amino acid sequence and glucose-lowering and insulin-sensitizing effects with GLP-1 [60, 61].”
BackgroundSTIMULATION OF INSULIN SECRETION BY GASTRIC INHIBITORY POLYPEPTIDE IN MAN. 1
Dupre, J., Ross, S. A., Watson, D., & Brown, J. C. (1973) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-37-5-826 · Cited by 860 · cited 2×
“Soon thereafter, the peptide was identified as an insulin secretagogue in humans [30].”
BackgroundGöke, R., Fehmann, H. C., Linn, T., Schmidt, H., Krause, M., Eng, J., & Göke, B. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)36565-2 · Cited by 837 · cited 1×
“…compared to endogenous GLP-1, exendin-4 has a C-terminal extended (CEX) amino acid sequence, along with substitution of the N-terminal alanine-2 residue with glycine, which makes the peptide resistant to degradation by DPP4, resulting in a significantly longer half-life than endogenous GLP-1 [62].”
BackgroundCardiovascular and renal outcomes with efpeglenatide in type 2 diabetes
Gerstein, H. C., Sattar, N., Rosenstock, J., Ramasundarahettige, C., Pratley, R., Lopes, R. D., Lam, C. S. P., Khurmi, N. S., Heenan, L., Del Prato, S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108269 · Cited by 829
Deacon, C. F., Johnsen, A. H., & Holst, J. J. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.3.7883856 · Cited by 792 · cited 1×
“GIP and GLP-1 are both degraded very quickly by dipeptidyl peptidase 4 (DPP4) [57–59], making analogues of these endogenous hormones poor drug candidates.”
BackgroundGarvey, W. T., Frias, J. P., Jastreboff, A. M., le Roux, C. W., Sattar, N., Aizenberg, D., Mao, H., Zhang, S., Ahmad, N. N., Bunck, M. C., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01200-x · Cited by 792
Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Finan, B., Ma, T., Ottaway, N., Müller, T. D., Habegger, K. M., Heppner, K. M., Kirchner, H., Holland, J., Hembree, J., Raver, C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007218 · Cited by 696 · cited 1×
“Developed using a similar approach as the GLP-1/glucagon dual agonist, a GLP-1/GIP dual agonist produced greater reductions in body weight than GLP-1 monoagonists alone in DIO mice [46, 47, 89].”
MethodSelf-citationDel Prato, S., Kahn, S. E., Pavo, I., Weerakkody, G. J., Yang, Z., Doupis, J., Aizenberg, D., Wynne, A. G., Riesmeyer, J. S., Heine, R. J., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02188-7 · Cited by 684
A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
Finan, B., Yang, B., Ottaway, N., Smiley, D. L., Ma, T., Clemmensen, C., Chabenne, J., Zhang, L., Habegger, K. M., Fischer, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3761 · Cited by 645 · cited 6×
“In 2015, Finan and colleagues designed and characterized in DIO mice the first monomeric triple gut hormone receptor agonist, targeting simultaneously not only GIPR and GLP-1R but also the GCGR [99].”
BackgroundResultInfluentialSelf-citationA new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.209 · Cited by 641 · cited 1×
“When both drugs were given to mice lacking the GLP-1R, the GLP-1-centric dual agonist produced no change in body weight while the balanced dual agonist still produced a significant reduction in body weight [81].”
BackgroundSelf-citationLudvik, B., Giorgino, F., Jódar, E., Frias, J. P., Fernández Landó, L., Brown, K., Bray, R., & Rodríguez, Á. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01443-4 · Cited by 639
Dahl, D., Onishi, Y., Norwood, P., Huh, R., Bray, R., Patel, H., & Rodríguez, Á. (2022) · JAMA · doi:10.1001/jama.2022.0078 · Cited by 597
Pratley, R. E., Nauck, M., Bailey, T., Montanya, E., Cuddihy, R., Filetti, S., Thomsen, A. B., Søndergaard, R. E., & Davies, M. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60307-8 · Cited by 586 · cited 1×
“This early success of this first GLP-1R agonist drug has been followed by a number of GLP-1 analogues, including liraglutide [64, 65] and semaglutide, which has completely transformed the landscape of obesity.”
BackgroundKnop, F. K., Aroda, V. R., do Vale, R. D., Holst-Hansen, T., Laursen, P. N., Rosenstock, J., Rubino, D. M., & Garvey, W. T. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01185-6 · Cited by 431
Rosenstock, J., Frias, J., Jastreboff, A. M., Du, Y., Lou, J., Gurbuz, S., Thomas, M. K., Hartman, M. L., Haupt, A., Milicevic, Z., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01053-x · Cited by 423 · cited 6×
“While the safety and tolerability profile of retatrutide is compel-lingly similar to that of GLP-1R monoagonism and GLP-1/GIP dual agonism [102, 103], its efficacy, especially regarding obesity and its effect on body weight loss, is again greater, bringing us closer to closing the gap with…”
BackgroundInfluentialThe New Biology and Pharmacology of Glucagon
Müller, T. D., Finan, B., Clemmensen, C., DiMarchi, R. D., & Tschöp, M. H. (2017) · Physiological Reviews · doi:10.1152/physrev.00025.2016 · Cited by 419 · cited 5×
“Therefore, glucagon acts not only to increase glucose production but also to induce lipolysis, fatty acid oxidation, ketogene-sis, increase thermogenesis and energy expenditure, bile acid synthesis, and finally induce satiation and reduce food intake [22, 23].”
BackgroundInfluentialSelf-citationThe metabolic actions of glucagon revisited
Habegger, K. M., Heppner, K. M., Geary, N., Bartness, T. J., DiMarchi, R., & Tschöp, M. H. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.187 · Cited by 406 · cited 2×
“Therefore, glucagon acts not only to increase glucose production but also to induce lipolysis, fatty acid oxidation, ketogene-sis, increase thermogenesis and energy expenditure, bile acid synthesis, and finally induce satiation and reduce food intake [22, 23].”
BackgroundSelf-citationAssociations of Muscle Mass and Strength with All-Cause Mortality among US Older Adults
LI, R., XIA, J., ZHANG, X., GATHIRUA-MWANGI, W. G., GUO, J., LI, Y., MCKENZIE, S., & SONG, Y. (2018) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000001448 · Cited by 398 · cited 1×
“However, as low muscle mass is associated with adverse health outcomes and higher all-cause mortality in older adults [112]”
BackgroundInsulin Secretion Depends on Intra-islet Glucagon Signaling
Svendsen, B., Larsen, O., Gabe, M. B. N., Christiansen, C. B., Rosenkilde, M. M., Drucker, D. J., & Holst, J. J. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.10.018 · Cited by 355 · cited 1×
“However, the classical model has evolved into a complex picture: insulin secretion depends on intra-islet glucagon signaling [21] and α -cells secrete glucagon in response to fatty acids, metabolites, paracrine, endocrine, and neuronal signals.”
BackgroundGlucose-Dependent Insulinotropic Polypeptide
Christensen, M., Vedtofte, L., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2011) · Diabetes · doi:10.2337/db11-0979 · Cited by 353
Adriaenssens, A. E., Biggs, E. K., Darwish, T., Tadross, J., Sukthankar, T., Girish, M., Polex-Wolf, J., Lam, B. Y., Zvetkova, I., Pan, W., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.07.013 · Cited by 324 · cited 1×
“Moreover, GIPR signaling in the hypothalamus regulates appetite and body weight [53].”
BackgroundNahra, R., Wang, T., Gadde, K. M., Oscarsson, J., Stumvoll, M., Jermutus, L., Hirshberg, B., & Ambery, P. (2021) · Diabetes Care · doi:10.2337/dc20-2151 · Cited by 323 · cited 1×
“The first GLP-1R/GCGR agonist to be put in clinical trials, cotadutide, produced comparable reductions in body weight and blood sugar levels in adults with overweight or obesity, and T2D as 1.8 mg of liraglutide [82].”
MethodInfluentialZhang, Q., Delessa, C. T., Augustin, R., Bakhti, M., Colldén, G., Drucker, D. J., Feuchtinger, A., Caceres, C. G., Grandl, G., Harger, A., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.01.015 · Cited by 322 · cited 5×
“An optimized GIP agonist, exhibiting full potency for the human GIPR that also acts as an agonist at the mouse GIPR, induced a reduction in body weight and blood glucose in GLP-1R knockout mice but not GIPR knockout mice [46, 86].”
BackgroundMethodInfluentialSelf-citationFrias, J. P., Bastyr, E. J., Vignati, L., Tschöp, M. H., Schmitt, C., Owen, K., Christensen, R. H., & DiMarchi, R. D. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.07.011 · Cited by 321 · cited 2×
“In the SURPASS trials, tirzepatide consistently outper-formed placebo and active comparators in reducing HbA1c across all doses [90, 93–96].”
MethodInfluentialSelf-citationKinlen, D., Cody, D., & O’Shea, D. (2018) · QJM: An International Journal of Medicine · doi:10.1093/qjmed/hcx152 · Cited by 308 · cited 1×
“Obesity is a major part of the problem, its complications including chronic kidney disease, hypertensive disease, stroke, and liver disease negatively impacting quality but also quantity of life as life expectancy decreases as body mass index (BMI) increases [3].”
BackgroundGut-Brain Cross-Talk in Metabolic Control
Clemmensen, C., Müller, T. D., Woods, S. C., Berthoud, H.-R., Seeley, R. J., & Tschöp, M. H. (2017) · Cell · doi:10.1016/j.cell.2017.01.025 · Cited by 297 · cited 1×
“Leptin and ghrelin are only two of many neuroendocrine signaling pathways facilitating peripheral-brain communication regulating metabolism [17, 18].”
BackgroundSelf-citationPancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem
Lund, P. K., Goodman, R. H., Dee, P. C., & Habener, J. F. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.2.345 · Cited by 295
Further purification of a polypeptide demonstrating enterogastrone activity
Brown, J. C., Mutt, V., & Pederson, R. A. (1970) · The Journal of Physiology · doi:10.1113/jphysiol.1970.sp009155 · Cited by 276 · cited 1×
“GIP was discovered in the early 1970s by John Brown and colleagues as the gastric-inhibitory polypeptide [28, 29].”
BackgroundHypoMap—a unified single-cell gene expression atlas of the murine hypothalamus
Steuernagel, L., Lam, B. Y. H., Klemm, P., Dowsett, G. K. C., Bauder, C. A., Tadross, J. A., Hitschfeld, T. S., del Rio Martin, A., Chen, W., de Solis, A. J., et al. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00657-y · Cited by 267 · cited 1×
“Consistent with the broad action of the incretins in the brain and the periphery, the receptors for GIP and GLP-1 receptors show widespread distribution that includes also hypothalamic and hindbrain regions implicated in regulation of body weight and food intake [52–55].”
BackgroundNagashima, M., Watanabe, T., Terasaki, M., Tomoyasu, M., Nohtomi, K., Kim-Kaneyama, J., Miyazaki, A., & Hirano, T. (2011) · Diabetologia · doi:10.1007/s00125-011-2241-2 · Cited by 259
Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
Hammoud, R., & Drucker, D. J. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00783-3 · Cited by 244 · cited 1×
“1 Synergies in mechanisms that regulate body weight and glucose metabolism by incretin agonism across tissues in humans [22, 23, 106].”
BackgroundGedulin, B. R., Nikoulina, S. E., Smith, P. A., Gedulin, G., Nielsen, L. L., Baron, A. D., Parkes, D. G., & Young, A. A. (2005) · Endocrinology · doi:10.1210/en.2004-1349 · Cited by 242 · cited 1×
“Exendin-4 shares a large portion of its amino acid sequence and glucose-lowering and insulin-sensitizing effects with GLP-1 [60, 61].”
BackgroundSargeant, J. A., Henson, J., King, J. A., Yates, T., Khunti, K., & Davies, M. J. (2019) · Endocrinology and Metabolism · doi:10.3803/enm.2019.34.3.247 · Cited by 231 · cited 1×
“This is a common problem associated with any form of body weight loss, and there is no evidence that incretin agonist treatment leads to a greater proportion of lean mass loss than other methods [111].”
ResultOptimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism
Mroz, P. A., Finan, B., Gelfanov, V., Yang, B., Tschöp, M. H., DiMarchi, R. D., & Perez-Tilve, D. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2018.12.001 · Cited by 229 · cited 3×
“To solve this problem, a variety of stable and long-acting GIP analogues have been developed and tested for binding efficiency and action on both human and mouse GIPRs [86].”
BackgroundResultSelf-citationRomero-Gómez, M., Lawitz, E., Shankar, R. R., Chaudhri, E., Liu, J., Lam, R. L. H., Kaufman, K. D., Engel, S. S., Bruzone, S. O., Coronel, M. J., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.05.013 · Cited by 220
Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy
Fonseca, V. A., Alvarado-Ruiz, R., Raccah, D., Boka, G., Miossec, P., Gerich, J. E., & on behalf of the EFC6018 GetGoal-Mono Study Investigators (2012) · Diabetes Care · doi:10.2337/dc11-1935 · Cited by 218
Activation of Lipoprotein Lipase by Glucose-dependent Insulinotropic Polypeptide in Adipocytes
Kim, S.-J., Nian, C., & McIntosh, C. H. S. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m609088200 · Cited by 216 · cited 1×
“Apart from stimulating the secretion of either insulin or glucagon in glucose-dependent manner [33], GIP promotes lipogenesis and lipid deposition under conditions of hyperin-sulinema [34–36] while stimulating lipolysis and fatty acid oxidation under conditions of normo-or hypoinsulinemia [37–39].”
BackgroundBorner, T., Geisler, C. E., Fortin, S. M., Cosgrove, R., Alsina-Fernandez, J., Dogra, M., Doebley, S., Sanchez-Navarro, M. J., Leon, R. M., Gaisinsky, J., et al. (2021) · Diabetes · doi:10.2337/db21-0459 · Cited by 202 · cited 2×
“In preclinical models, the addition of GIPR agonism to GLP-1R agonism attenuates emesis while increasing the amount of body weight reduction compared to GLP-1 agonism alone [98].”
BackgroundInterrelationship of Glucagon, Insulin and Glucose: The Insulinogenic Effect of Glucagon
Samols, E., Marri, G., & Marks, V. (1966) · Diabetes · doi:10.2337/diab.15.12.855 · Cited by 199 · cited 1×
“Consistent with the observation that glucagon acts on the pancreatic β -cells to stimulate insulin secretion via the GLP-1 receptor (GLP-1R) [24–27], long-term treatment of diet-induced obese (DIO) mice with a biochemically modified water-soluble glucagon improved glucose metabolism with equal…”
BackgroundPreparation of highly active enterogastrone
Brown, J. C., Pederson, R. A., Jorpes, E., & Mutt, V. (1969) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y69-020 · Cited by 189 · cited 1×
“GIP was discovered in the early 1970s by John Brown and colleagues as the gastric-inhibitory polypeptide [28, 29].”
BackgroundRelative quantitative analysis of glucagon receptor mRNA in rat tissues
Svoboda, M., Tastenoy, M., Vertongen, P., & Robberecht, P. (1994) · Molecular and Cellular Endocrinology · doi:10.1016/0303-7207(94)90162-7 · Cited by 169 · cited 2×
“GCGR is expressed in liver, brain, kidney, preadi-pocytes, pancreas, and heart [20, 80].”
BackgroundZhao, F., Zhou, Q., Cong, Z., Hang, K., Zou, X., Zhang, C., Chen, Y., Dai, A., Liang, A., Ming, Q., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28683-0 · Cited by 149 · cited 1×
“2 A The amino acid sequence of a GLP-1R/GCGR dual agonist MK1462 [116], B the amino acid sequence of the GLP-1R/GIPR dual agonist tirzepatide [117], and C the amino acid sequence of a triagonist [99].”
BackgroundCampbell, J. E., Müller, T. D., Finan, B., DiMarchi, R. D., Tschöp, M. H., & D’Alessio, D. A. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.07.010 · Cited by 149
Self-citationAnglerfish islet pre-proglucagon II. Nucleotide and corresponding amino acid sequence of the cDNA
Lund, P. K., Goodman, R. H., Montminy, M. R., Dee, P. C., & Habener, J. F. (1983) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)32858-8 · Cited by 146 · cited 1×
“GLP-1 was discovered by Svetlana Mojsov and Joel Habener in the early 1980s [48–50].”
BackgroundGlucose-dependent insulinotropic peptide-overexpressing transgenic mice have increased bone mass
Xie, D., Zhong, Q., Ding, K.-H., Cheng, H., Williams, S., Correa, D., Bollag, W. B., Bollag, R. J., Insogna, K., Troiano, N., et al. (2007) · Bone · doi:10.1016/j.bone.2007.01.007 · Cited by 144 · cited 1×
“GIPR agonism further promotes bone formation [40], has beneficial effects in animal models for atherosclerosis [41–43] and neurodegenerative diseases [44, 45], and decreases body weight in obese rodents via inhibition of food intake [46, 47].”
BackgroundMurlin, J. R., Clough, H. D., Gibbs, C. B. F., & Stokes, A. M. (1923) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)85619-8 · Cited by 141
Kim, S.-J., Nian, C., & McIntosh, C. H. S. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m006841 · Cited by 133 · cited 1×
“Apart from stimulating the secretion of either insulin or glucagon in glucose-dependent manner [33], GIP promotes lipogenesis and lipid deposition under conditions of hyperin-sulinema [34–36] while stimulating lipolysis and fatty acid oxidation under conditions of normo-or hypoinsulinemia [37–39].”
BackgroundTargeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms
Campbell, J. E. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101139 · Cited by 133 · cited 1×
“Contrary to early loss of function studies that suggested that GIPR drove an increase in body weight, there is no evidence that GIPR agonism increases body weight [85, 86].”
ResultGastric inhibitory polypeptide does not inhibit gastric emptying in humans
Meier, J. J., Goetze, O., Anstipp, J., Hagemann, D., Holst, J. J., Schmidt, W. E., Gallwitz, B., & Nauck, M. A. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00499.2003 · Cited by 126
Kim, S.-J., Nian, C., & McIntosh, C. H. S. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704896200 · Cited by 118
The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets
El, K., Douros, J. D., Willard, F. S., Novikoff, A., Sargsyan, A., Perez-Tilve, D., Wainscott, D. B., Yang, B., Chen, A., Wothe, D., et al. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00811-0 · Cited by 118 · cited 1×
“So far we know tirzepatide drives insulin secretion primarily via GIPR in human islets [108].”
BackgroundSelf-citationJi, L., Jiang, H., Cheng, Z., Qiu, W., Liao, L., Zhang, Y., Li, X., Pang, S., Zhang, L., Chen, L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-44067-4 · Cited by 118
Sparre‐Ulrich, A. H., Hansen, L. S., Svendsen, B., Christensen, M., Knop, F. K., Hartmann, B., Holst, J. J., & Rosenkilde, M. M. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13323 · Cited by 114 · cited 1×
“Developing GIPR agonists has an additional challenge compared with glucagon and GLP-1, as the endogenous human and mouse GIPs differ slightly; human GIP is a poor agonist for the mouse GIPR [87, 88].”
BackgroundLiskiewicz, A., Khalil, A., Liskiewicz, D., Novikoff, A., Grandl, G., Maity-Kumar, G., Gutgesell, R. M., Bakhti, M., Bastidas-Ponce, A., Czarnecki, O., et al. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00931-7 · Cited by 110 · cited 4×
“In a recent study Liskiewicz and colleagues found that GABAergic neurons expressing the GIPR in the area postrema are activated by long-acting GIPR agonists, and GIPR signaling in GABAergic neurons is required for the body weight-lowering effects of GIP [47].”
BackgroundMethodInfluentialSelf-citationThe past, present, and future physiology and pharmacology of glucagon
Capozzi, M. E., D’Alessio, D. A., & Campbell, J. E. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.10.001 · Cited by 109
Holscher, C. (2010) · Recent Patents on CNS Drug Discovery · doi:10.2174/157488910791213130 · Cited by 102 · cited 1×
“GIPR agonism further promotes bone formation [40], has beneficial effects in animal models for atherosclerosis [41–43] and neurodegenerative diseases [44, 45], and decreases body weight in obese rodents via inhibition of food intake [46, 47].”
BackgroundGut hormone co-agonists for the treatment of obesity: from bench to bedside
Nogueiras, R., Nauck, M. A., & Tschöp, M. H. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00812-z · Cited by 102 · cited 1×
“2) [5, 23, 104–107].”
Self-citationA survey of the mouse hindbrain in the fed and fasted states using single-nucleus RNA sequencing
Dowsett, G. K. C., Lam, B. Y. H., Tadross, J. A., Cimino, I., Rimmington, D., Coll, A. P., Polex-Wolf, J., Knudsen, L. B., Pyke, C., & Yeo, G. S. H. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101240 · Cited by 98
Nogi, Y., Nagashima, M., Terasaki, M., Nohtomi, K., Watanabe, T., & Hirano, T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035683 · Cited by 96 · cited 1×
“GIPR agonism further promotes bone formation [40], has beneficial effects in animal models for atherosclerosis [41–43] and neurodegenerative diseases [44, 45], and decreases body weight in obese rodents via inhibition of food intake [46, 47].”
BackgroundJi, L., Gao, L., Jiang, H., Yang, J., Yu, L., Wen, J., Cai, C., Deng, H., Feng, L., Song, B., et al. (2022) · eClinicalMedicine · doi:10.1016/j.eclinm.2022.101691 · Cited by 83 · cited 1×
“Developing GIPR agonists has an additional challenge compared with glucagon and GLP-1, as the endogenous human and mouse GIPs differ slightly; human GIP is a poor agonist for the mouse GIPR [87, 88].”
BackgroundLEAP2 reduces postprandial glucose excursions and ad libitum food intake in healthy men
Hagemann, C. A., Jensen, M. S., Holm, S., Gasbjerg, L. S., Byberg, S., Skov-Jeppesen, K., Hartmann, B., Holst, J. J., Dela, F., Vilsbøll, T., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100582 · Cited by 81 · cited 1×
“Likewise, while ghrelin has the potential to be a useful treatment for cancer cachexia [14], strategies for inhibiting ghrelin signaling have thus far not produced viable pharmacotherapies for obesity, but this is an ongoing area of research [15, 16].”
BackgroundMcIntosh, C. H. S., Bremsak, I., Lynn, F. C., Gill, R., Hinke, S. A., Gelling, R., Nian, C., McKnight, G., Jaspers, S., & Pederson, R. A. (1999) · Endocrinology · doi:10.1210/endo.140.1.6464 · Cited by 73
Pancreatic pre-proglucagons are encoded by two separate mRNAs
Lund, P. K., Goodman, R. H., & Habener, J. F. (1981) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)69015-0 · Cited by 70 · cited 1×
“GLP-1 was discovered by Svetlana Mojsov and Joel Habener in the early 1980s [48–50].”
BackgroundNeuroprotective effects of glucose-dependent insulinotropic polypeptide in Alzheimer’s disease
Ji, C., Xue, G.-F., Li, G., Li, D., & Hölscher, C. (2016) · Reviews in the Neurosciences · doi:10.1515/revneuro-2015-0021 · Cited by 68
Nauck, M. A., Bartels, E., Ørskov, C., Ebert, R., & Creutzfeldt, W. (2009) · Digestion · doi:10.1159/000200956 · Cited by 54 · cited 1×
“Since the insuli-notropic but not the gastric-inhibitory action of GIP prevailed at physiological concentrations [30–32], the peptide was later renamed glucose-dependent insulinotropic polypeptide.”
BackgroundGhrelin for the management of cachexia associated with cancer
Khatib, M. N., Shankar, A. H., Kirubakaran, R., Gaidhane, A. M., Gaidhane, S., Simkhada, P. P., & Zahiruddin, Q. S. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012229.pub2 · Cited by 54 · cited 1×
“Likewise, while ghrelin has the potential to be a useful treatment for cancer cachexia [14], strategies for inhibiting ghrelin signaling have thus far not produced viable pharmacotherapies for obesity, but this is an ongoing area of research [15, 16].”
BackgroundAbdelmalek, M. F., Suzuki, A., Sanchez, W., Lawitz, E., Filozof, C., Cho, H., Baek, E., Choi, J., & Baek, S. (2023) · Contemporary Clinical Trials · doi:10.1016/j.cct.2023.107176 · Cited by 51 · cited 1×
“HM15211 is currently undergoing phase 2 clinical trial for the treat-ment of NASH [101].”
BackgroundDel Prato, S., Kang, J., Trautmann, M. E., Stewart, J., Sorli, C. H., Derwahl, M., Soto, A., & Yoon, K. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14020 · Cited by 43
Evaluation of commercially available glucagon receptor antibodies and glucagon receptor expression
Bomholt, A. B., Johansen, C. D., Christensen, J. B., Kjeldsen, S. A. S., Galsgaard, K. D., Winther-Sørensen, M., Serizawa, R., Hornum, M., Porrini, E., Pedersen, J., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-04242-7 · Cited by 42 · cited 1×
“GCGR is expressed in liver, brain, kidney, preadi-pocytes, pancreas, and heart [20, 80].”
BackgroundSeeking satiety: From signals to solutions
Tschöp, M. H., & Friedman, J. M. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adh4453 · Cited by 30 · cited 1×
“Leptin and ghrelin are only two of many neuroendocrine signaling pathways facilitating peripheral-brain communication regulating metabolism [17, 18].”
BackgroundSelf-citationGLP-1/dexamethasone inhibits food reward without inducing mood and memory deficits in mice
Décarie-Spain, L., Fisette, A., Zhu, Z., Yang, B., DiMarchi, R. D., Tschöp, M. H., Finan, B., Fulton, S., & Clemmensen, C. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.03.035 · Cited by 27 · cited 1×
“In line with this, mice treated with a GLP-1R/dexamethasone conjugate displayed a reduction in food-motivated behavior versus GLP-1R agonism alone, without increasing anxiodepressive behavior and memory [109].”
BackgroundSelf-citationLE ROUX, C., STEEN, O., LUCAS, K. J., STARTSEVA, E., UNSELD, A., & HENNIGE, A. M. (2023) · Diabetes · doi:10.2337/db23-51-or · Cited by 24
Sachs, S., Götz, A., Finan, B., Feuchtinger, A., DiMarchi, R. D., Döring, Y., Weber, C., Tschöp, M. H., Müller, T. D., & Hofmann, S. M. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01940-2 · Cited by 24 · cited 1×
“GIPR agonism further promotes bone formation [40], has beneficial effects in animal models for atherosclerosis [41–43] and neurodegenerative diseases [44, 45], and decreases body weight in obese rodents via inhibition of food intake [46, 47].”
BackgroundSelf-citationDual gut hormone receptor agonists for diabetes and obesity
Bass, J., Tschöp, M. H., & Beutler, L. R. (2023) · Journal of Clinical Investigation · doi:10.1172/jci167952 · Cited by 21
Self-citationHeimburger, S. M. N., Nielsen, C. N., Calanna, S., Holst, J. J., Vilsbøll, T., Knop, F. K., & Christensen, M. B. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14545 · Cited by 13
Palani, A., Nawrocki, A. R., Orvieto, F., Bianchi, E., Mandić, E., Pessi, A., Huang, C., Deng, Q., Toussaint, N., Walsh, E., et al. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00217 · Cited by 12 · cited 1×
“2 A The amino acid sequence of a GLP-1R/GCGR dual agonist MK1462 [116], B the amino acid sequence of the GLP-1R/GIPR dual agonist tirzepatide [117], and C the amino acid sequence of a triagonist [99].”
BackgroundFarahani, R. A., Egan, A. M., Welch, A. A., LAURENTI, M. C., Cobelli, C., Man, C. D., & Vella, A. V. (2022) · Diabetes · doi:10.2337/db22-0709 · Cited by 12
Gut Regulatory Peptides: Their Role in Health and Disease
Walsh, D. (1988) · Clinica Chimica Acta · doi:10.1016/0009-8981(88)90043-5 · Cited by 10
Glucagon as the First Incretin: Objects (in the Rearview Mirror) Are Closer Than They Appear
D’Alessio, D. A., & Marks, V. (2023) · Diabetes · doi:10.2337/dbi26-0026 · Cited by 5
Roux, M. C. W. L., Steen, O., Lucas, K. J., Startseva, E., Borowska, L., & Unseld, A. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155848 · Cited by 1
Research works printed but not linked: 2
- IDF Diabetes Atlas 10th edition. International Diabetes Federation; 2021. (IDF Diabetes Atlas). Report no. 10. https://diabetesatlas.org/atlas/tenth-edition/.
- Ji L Gao L Jiang H Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: a randomised, placebo-controlled, multiple-ascending-dose phase 1b trial EClinicalMedicine 2022 54 101691 10.1016/j.eclinm.2022.101691 36247927 PMC9561728 · DOI · Paper page
Cited by
GPCR drug discovery: new agents, targets and indications
Lorente, J. S., Sokolov, A. V., Ferguson, G., Schiöth, H. B., Hauser, A. S., & Gloriam, D. E. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01139-y · Cited by 251
Billings, L. K., Hsia, S. H., Bays, H. E., Tidemann‐Miller, B., O’Hagan, J., Tham, L. S., Butler, A., KAZDA, C. M., Mather, K. J., & Coşkun, T. (2025) · The Lancet · doi:10.1016/s0140-6736(25)02155-5 · Cited by 47
Amylin: From Mode of Action to Future Clinical Potential in Diabetes and Obesity
Volčanšek, Š., Koceva, A., Jensterle, M., Janež, A., & Muzurović, E. M. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01733-8 · Cited by 35
Anastasiou, I. A., Argyrakopoulou, G., Dalamaga, Μ., & Kokkinos, A. D. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00623-1 · Cited by 29
“…exact mechanisms underlying the weight loss are still not clear, especially in light of the enhanced effects seen with multi-agonism, despite the large number of incretin agonists presently undergoing clinical trials and their remarkable effectiveness in managing obesity and T2DM [5, 14, 146, 147].”
Ostrominski, J. W., Ortega-Montiel, J., Tesfaye, H., ALIX, C., DiCesare, E., CROMER, S. J., Wexler, D. J., Paik, J. M., & Patorno, E. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-02870 · Cited by 29
Metadata
- Authors
- Gutgesell, R. M., Nogueiras, R., Tschöp, M. H., & Müller, T. D.
- Affiliations
- Helmholtz Munich (DE)
- Universidade de Santiago de Compostela (ES)
- Corresponding author
- Müller, Timo D.
- Venue
- Diabetes Therapy
- Published
- 2024-04-04
- Volume
- 15
- Issue
- 5
- Pages
- 1069-1084
- ISSN
- 1869-6953 (ISSN-L)
- 1869-6961
- PMC
- PMC11043266
- OpenAlex
- W4393932284
- Semantic Scholar
- 5c836077804f02f246d45c218f15d363cf31e9e6
- Cited by
- 61
- References
- 113
- Citations by year
- 2026: 22 · 2025: 33 · 2024: 6
- FWCI
- 3.56
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Locations
- Diabetes Therapy (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion, cc-by-nc)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Funders
- European Research Council (ERC-CoG Trusted no.101044)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- exendin-4, obesity, type 2 diabetes, glucose-dependent insulinotropic polypeptide, GLP-1 receptor, glucagon receptor, weight loss, gut-brain signaling, bariatric surgery alternatives
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.